Latest Stock Market News

The brokerage estimates a ~19% PAT CAGR over FY22-25, with RoA/RoE at 2.0%/17.7% in FY25. Further, it expects the stock to perform gradually as the margin profile revives and the merger-related overhang eases.

“I do not think the commodity increase should be viewed as a market signalling there is going to be great demand. I would just hasten to caution that one should not be looking at increasing equity exposure despite all the positive noise we may see. This is a market which will remain extremely volatile during the course of the year.”

A total of 5,845 shares changed hands on the counter till 10:46AM (IST)

The Nifty Pharma index was trading 0.33 per cent down at 12627.45.

The stock quoted a 52-week high price of Rs 1509.25 and low of Rs 1002.5.

Promoters held 67.24 per cent stake in the company as of 30-Sep-2022, while FIIs owned 20.23 per cent, DIIs 6.43 per cent.

It is trading within its all-important moving averages. On the higher time frame, there is a long consolidation and is trying to bottom the structure, which suggests much more upside potential in this counter.

This multibagger stock from the garments and apparels segment is scheduled to meet for its board meeting for considering bonus share issue and stock split. The company’s stock in a 1-year period has generated a return of 578

The brokerage maintains a Buy rating on Infosys with an unchanged PT of Rs. 1,730 given strong deal pipeline, its end -to-end capabilities and prowess in digital areas, analytics, automation and Cobalt cloud.

“We should be prepared for a reasonably volatile first half followed by rebound or a positive back half of the year. In the volatile first half, one should invest in tranches and there are four or five themes that I would be bullish on investing in from a 3-year perspective.”